title: [Presurgical treatment of axitinib reduced operation risk by downsizing the vena cava tumor thrombus in advanced renal cell carcinomas: two case reports].
abstract: In cases of advanced renal cell carcinoma with inferior vena cava (IVC) thrombus, surgical resection of both tumor and thrombus contributes to the improvement of patient's prognosis, but the risk of perioperative complication is still high. We experienced two cases of advanced renal tumors with IVC tumor thrombus down-sized by presurgical treatment of axitinib. Axitinib treatment showed a marked tumor reduction effect without any severe adverse event. We could remove both tumor and thrombus without perioperative complications. In these two cases, downsizing of IVC thrombus enabled us to reduce the extent of the surgery.
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Hamada
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Toshinari
authors.initials: T
authors.lastname: Yamasaki
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Hiromitsu
authors.initials: H
authors.lastname: Negoro
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Takashi
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Naoki
authors.initials: N
authors.lastname: Terada
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Sugino
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Matsui
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Inoue
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kamba
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Koji
authors.initials: K
authors.lastname: Yoshimura
authors.affiliation: The Department of Urology, Graduate School of Medicine, Kyoto University.
authors.forename: Osamu
authors.initials: O
authors.lastname: Ogawa
mesh_terms: D000368:Aged; D000077784:Axitinib; D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000601:surgery*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007191:Indazoles / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011300:Preoperative Care; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D014682:Vena Cava, Inferior
chemical_list: D007093:Imidazoles; D007191:Indazoles; D047428:Protein Kinase Inhibitors; D000077784:Axitinib